"ChatGPT for doctors" is valued at $6 billion

Just three months after raising $200 million at a $6 billion valuation, OpenEvidence, the so-called "ChatGPT for doctors," made an incredible valuation leap. Its prior round had valued it at $3.5 billion. The specifics: More than 40% of American physicians and more than 10,000 institutions currently use the clinical AI developed by the Miami-based startup for quick, fact-based responses. To provide completely sourced, evidence-based responses, our AI is trained solely on peer-reviewed medical literature from journals like NEJM and JAMA. Daniel Nadler, a Harvard-trained economist, founded OpenEvidence, which has been compared to Google Search in the medical field. The website synthesizes data from 35 million medical publications and conducts millions of consultations each month; doctors can use it for free thanks to an ad-supported approach. The company's $6 billion increase in less than a year demonstrates where investor confidence appears to be going: AI designed for professional, high-stakes applications rather than generic chatbots. You're establishing the true meaning of trusted machine intelligence when your product becomes the default in life-or-death situations.